Development of Sedative Dexmedetomidine Sublingual In Situ Gels: In Vitro and In Vivo Evaluations

Area of Science:

• Pharmacology
• Drug Delivery Systems
• Anesthesiology

Background:

• Intravenous dexmedetomidine (DEX) is FDA-approved for intensive care unit sedation and postoperative analgesia.
• Common limitations of intravenous DEX include bradycardia and hypotension.
• Alternative administration routes are needed to mitigate these adverse effects.

Purpose of the Study:

• To develop and characterize dexmedetomidine (DEX) sublingual in situ gels.
• To evaluate the in vivo performance and safety profile of the sublingual DEX gel compared to oral and intravenous administration.

Main Methods:

• Development and assessment of DEX sublingual in situ gels for pH, gelling capacity, viscosity, mucoadhesion, and in vitro drug release.
• In vivo pharmacokinetic and pharmacodynamic studies in animal models (rats and rabbits).
• Comparison of sublingual gel with oral solution and intravenous DEX administration.

Main Results:

• The optimized sublingual gel exhibited enhanced mucoadhesion, superior gelling capacity, and suitable rheological properties.
• Sublingual DEX gel demonstrated significantly higher bioavailability compared to oral administration.
• Sublingual administration achieved comparable plasma levels to intravenous DEX but with reduced systemic adverse reactions and sustained analgesia.

Conclusions:

• Sublingual administration of DEX in situ gel is a promising alternative for sedation and analgesia.
• This approach circumvents the adverse reactions associated with intravenous DEX administration.
• The developed sublingual gel offers improved efficacy and safety for DEX delivery.